Antibody-Drug Conjugates

© Getty Images

CPHI North America 2024

Piramal Pharma unveils expanded services and growth vision

By Isabel Cameron

What is ADC specialist Piramal Pharma planning for the upcoming CPHI North America conference? We sat down with chief commercial officer Stuart Needleman to find out what's on the company's agenda.

© Getty Images

Hired and retired: New appointments in the pharma industry

By Isabel Cameron

BioPharma Reporter and Outsourcing Pharma presents its latest round-up of the movers, shakers and key announcements in the pharma industry. From Stand Up To Cancer, Astraveus and KBI Biopharma, we break down the key changes.

© Getty Images

WuXi Biologics bioconjugates spinout plans $470 million IPO

By Liza Laws

The Chinese contract research, development and manufacturing organization (CRDMO) WuXi XDC has launched a bid to raise up to HK$3.7 billion (US$470.3 million) in an initial public offering (IPO) on the Hong Kong Stock Exchange.

© Getty Images

ADC licensing deals reached peak of $16.6 billion in 2022

By Isabel Cameron

The biopharmaceutical industry witnessed a 400% growth in total deal value of antibody-drug conjugate (ADC) licensing agreements from 2017-2022 and reached a peak of $16.6 billion in 2022, reveals data and analytics company GlobalData.

© Getty Images

SOTIO expands ADC pipeline with Synaffix tie up

By Isabel Cameron

Synaffix, a Lonza company commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), has entered a licensing agreement with SOTIO, a clinical stage immuno-oncology company owned by PPF Group.

© Getty Images

Fujifilm Diosynth builds advanced therapy manufacturing facility in UK

By Jonathan Smith

The contract development and manufacturing organization (CDMO) Fujifilm Diosynth Biotechnologies has completed a UK manufacturing facility for the production of advanced therapies including viral gene therapies, oncolytic viruses and viral vaccines for...

Pic:getty

Samsung Ventures invests in Araris Biotech in emerging ADC strategy

By Jonathan Smith

Samsung Ventures, the global investment arm of Samsung Group, has invested an undisclosed amount in the Swiss company Araris Biotech. The deal is independent from Araris’ ongoing Series A fundraising and will be used to bankroll the development of antibody-drug...

© Getty Images

Adcendo raises $34 million to fund ADC treatments for sarcoma

By Jonathan Smith


The Danish biotech Adcendo has bagged a Series A extension round of €31 million ($33.8 million), taking its Series A winnings so far to €82 million ($89.5 million). The round will bankroll the development of Adcendo’s pipeline of antibody-drug...

Follow us

Webinars

Headlines